Lymphoma

Molecular and cellular characteristics of commercial chimeric antigen receptor T-cell therapies appeared associated with treatment response and toxicity among patients with large B-cell lymphoma, according to a study in Nature Medicine.

Last week, the FDA approved margetuximab-cmkb for the treatment of patients with metastatic HER2-positive breast cancer. It was the top story in hematology/oncology.

The FDA cleared an investigational new drug application for LB1901, a chimeric antigen receptor T-cell therapy in development for treatment of adults with relapsed or refractory T-cell lymphoma, according to the agent’s manufacturer.

First-line therapy with axicabtagene ciloleucel induced an objective response in 85% of patients with high-risk large B-cell lymphoma, according to phase 2 study results presented at the virtual ASH Annual Meeting and Exposition.

Researchers have identified CD58 status as a predictive marker for durable responses to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.

More than 90% of patients with advanced-stage indolent non-Hodgkin lymphoma had an objective response to treatment with axicabtagene ciloleucel, according to data presented at the virtual ASH Annual Meeting and Exposition.

The FDA granted priority review to loncastuximab tesirine for treatment of relapsed or refractory diffuse large B-cell lymphoma, according to the agent’s manufacturer.

The FDA for a second time delayed a decision on a biologics license application for lisocabtagene maraleucel, a chimeric antigen receptor T-cell therapy for the treatment of adults with relapsed or refractory large B-cell lymphoma.

Pembrolizumab followed by doxorubicin, vinblastine and dacarbazine appeared safe and effective for newly diagnosed classical Hodgkin lymphoma, including for patients with bulky disease, according to phase 2 study results published in Blood.

ASH announced the election of four new members to its executive committee.